Navigating Recent Advances in Alzheimer’s Disease: Expert Insights on Neuropathological Diagnostic Markers and the Clinical Potential of Novel Disease-Modifying Therapies

CME: 0.5

Target Audience

This activity has been designed to meet the educational needs of dementia specialists, neurologists, primary care physicians, and advanced practice providers in neurology and primary care.

Program Overview

Early and accurate diagnosis of Alzheimer’s disease (AD) allows for patients to receive care earlier in the disease, which is especially important in the current landscape of emerging disease-modifying therapies (DMTs) for AD. The incorporation of biomarkers can further augment the diagnostic process to aid in earlier diagnosis of AD and prompt therapeutic intervention. In this educational podcast, join faculty Richard S. Isaacson, MD, and Charles P. Vega Jr, MD, as they provide an expert review on the association between biomarkers and clinical symptoms of AD, the use of biomarkers for early detection of AD, and the use of available and emerging DMTs for AD.

Learning Objectives

Upon completion of this activity, learners should be better able to:

  • OUTLINE the temporal association between AD neuropathological markers and clinical symptoms for early recognition and staging of AD
  • IMPLEMENT validated fluid and imaging biomarkers for the early detection of AD neuropathology
  • ASSESS the potential of available and emerging DMTs for AD according to their clinical efficacy, safety, and mechanism of action

Post a comment to this article